Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Profound Medical Corp.TSX: PRN.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $5.18M rose 7.6% year over year, behind the +17.5% change in trailing-twelve-month research & development. Sequentially, it rose 19.3% from the prior quarter. Over 3 fiscal years it compounded at +12.6% a year.

Context

  • Research & development amounted to 127.9% of revenue in FY2025, down 30.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.6% toward the trailing-twelve-month pace of +17.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.18M+19.3% QoQ
Last fiscal yearDec 2025
$20.96M+23.5% YoY
LTMMar 2026
$20.97M+17.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+23.5%——
3-year CAGR+12.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
20.96M USD
Year-over-year change
+23.5%
4-year CAGR
+8.2%

Research & Development vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.5% is the lowest of 3, against a peer median of +101.3%.
  • Research & development amounts to 111.8% of revenue for PRN.TO, versus a peer median of 0.0%.
PRN.TO Competitors
Research & Development for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.07M USD+139.8%+7.0%—
PRN.TOProfound Medical Corp.LTM Mar 2026$20.97M USD+17.5%+12.6%111.8%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$267K CAD+62.8%—0.2%
DR.TOMedical Facilities CorporationLTM Mar 2026$0 USD——0.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$0 CAD——0.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding PRN.TO) —+101.3%+7.0%0.0%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.